Showing results (191-200 of 310) with videos related to

Sort By:
Pageof 31
Nucleic Acids Research|September 18, 2014
cnvCapSeq: detecting copy number variation in long-range targeted resequencing dataEvangelos Bellos, Vikrant Kumar, Clarabelle Lin, et al.
Ophthalmology Science|November 29, 2023
Relationship Between Retinal Layer Thickness and Genetic Susceptibility to Age-Related Macular Degeneration in Asian PopulationsKai Xiong Cheong, Hengtong Li, Yih Chung Tham, et al.
Scientific Reports|March 10, 2022
Three-dimensional modelling of the choroidal angioarchitecture in a multi-ethnic Asian populationKai Xiong Cheong, Kelvin Yi Chong Teo, Yih Chung Tham, et al.
International Journal of Molecular Sciences|June 25, 2020
Investigating the Role of PPARβ/δ in Retinal Vascular Remodeling Using Pparβ/δ-Deficient MiceSze Yuan Ho, Yuet Ping Kwan, Beiying Qiu, et al.
The British Journal of Ophthalmology|February 12, 2021
Efficacy of a novel personalised aflibercept monotherapy regimen based on polypoidal lesion closure in participants with polypoidal choroidal vasculopathyKelvin Yi Chong Teo, Janice Marie Jordan-Yu, Anna C S Tan, et al.
Investigative Ophthalmology & Visual Science|April 28, 2021
IMI Pathologic MyopiaKyoko Ohno-Matsui, Pei-Chang Wu, Kenji Yamashiro, et al.
Ophthalmology Science|October 24, 2022
Serum Cholesterol Efflux Capacity in Age-Related Macular Degeneration and Polypoidal Choroidal VasculopathyYasuo Yanagi, Richard M C Yu, Waseem Ahamed, et al.
Clinical Ophthalmology (Auckland, N.Z.)|September 24, 2015
Conversion to aflibercept for diabetic macular edema unresponsive to ranibizumab or bevacizumabLaurence S Lim, Wei Yan Ng, Ranjana Mathur, et al.
BMJ Open|July 16, 2021
Multicentre, randomised clinical trial comparing intravitreal aflibercept monotherapy versus aflibercept combined with reduced-fluence photodynamic therapy (RF-PDT) for the treatment of polypoidal choroidal vasculopathyChinmayi Himanshuroy Vyas, Chui Ming Gemmy Cheung, Colin Tan, et al.
Eye (London, England)|April 9, 2022
Efficacy, safety, and treatment burden of treat-and-extend versus alternative anti-VEGF regimens for nAMD: a systematic review and meta-analysisDaniel Rosenberg, Deven M Deonarain, Jonah Gould, et al.
Pageof 31